MetaCap

HUTCHMED (China) (HCM) vs Pharvaris N.V. (PHVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pharvaris N.V. (PHVS) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 26.0% versus a loss of 5.6%. Over five years, PHVS leads with a +131.3% price change compared with -62.4% for HCM. HUTCHMED (China) is the larger company by market cap ($2.30 billion vs $2.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCM-5.57%PHVS+25.98%
+61%+14%-33%
Nov 21, 20251 yearNov 20, 2026
HCM-56.97%PHVS+100.90%
+156%+28%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCM versus PHVS key metrics
MetricHCMPHVS
Share price$13.22$31.28
Market cap$2.30B$2.21B
1-day change-1.71%-1.20%
YTD return-0.83%+12.72%
1-year return-5.57%+25.98%
5-year return-62.42%+131.28%
P/E ratio (TTM)132.20—
Forward P/E51.00—
EPS (TTM)$0.10$-3.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$548.51M—
Revenue growth (YoY)-12.96%—
Net income (latest FY)$456.91M$-25.99M
Gross margin38.68%—
Operating margin-7.14%—
Net margin83.30%—
52-week high$16.33$43.25
52-week low$9.77$23.15
Distance from 52-week high-19.04%-27.68%
Analyst consensusnonestrong_buy
Avg. price target upside+59.91%+86.29%
Average volume64.48K756.20K
Shares outstanding173.81M70.79M
Employees1,790168
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHVS has outperformed HCM by 31.5 percentage points over the past year.

About HUTCHMED (China)

HCM stock →

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees

About Pharvaris N.V.

PHVS stock →

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees

HCM vs PHVS FAQ

Which is bigger, HUTCHMED (China) or Pharvaris N.V.?

HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.30B compared with $2.21B for Pharvaris N.V. (PHVS).

Which stock has performed better over the past year, HCM or PHVS?

PHVS returned +25.98% over the past 12 months, compared with -5.57% for HCM (price return, excluding dividends). Past performance does not predict future results.

Are HUTCHMED (China) and Pharvaris N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons